Javascript must be enabled to continue!
Abstract 5879: An optimized sample-to-result workflow for detection of tumor mutations and immune sequencing in liquid biopsies
View through CrossRef
Abstract
Non-invasive liquid biopsies are helping advance various aspects of disease assessment including early detection, disease monitoring, and therapy selection, while also allowing for improved patient follow-up and economic efficiency over traditional tissue biopsies. Plasma cell-free DNA (cfDNA) applications have recently been adopted in prenatal screening, tumor mutation profiling and post-transplant monitoring. Additionally, combining cfDNA profiling with paired RNA analysis of peripheral blood mononuclear cells (PBMCs) can provide useful insights into biomarkers and immune phenotypes, and present a comprehensive multiomic profile from a single blood draw. Several technical and analytical challenges persist in the liquid biopsy field including immediate preservation of draw time levels of cfDNA, minimizing PBMC lysis during storage, low concentrations of cfDNA with even lower tumor fraction, as well as the need for a higher sensitivity in downstream applications to accurately interpret clinical signals. Here, we present an efficient blood-to-result workflow for tumor-specific mutation detection and immune profiling using contrived samples spiked with known mutation controls. Whole blood was collected in Streck Nucleic Acid BCT enabling preservation of draw time concentration of cell-free nucleic acids and prevention of immune cell lysis. Nucleic acid extraction was performed on the isolated PBMCs and plasma fraction using an optimized protocol for the Monarch Mag Viral DNA/RNA Extraction Kit which features a simplified, magnetic bead-based workflow. Isolated cfDNA was used to prepare sequencing libraries using an optimized library prep workflow to maximize conversion efficiency from cfDNA. Isolated PBMC RNA was utilized to prepare RNA-seq libraries and Immune-seq libraries using the NEBNext UltraExpress RNA Library Prep Kit and NEBNext Immune Sequencing Kit, respectively. Combining these sample storage, extraction, and library prep methods resulted in a high yield of cfDNA libraries with minimal contaminating genomic DNA, enabling improved sequencing data quality, high conversion efficiency, and high sensitivity for clinical research, including detecting spike-in mutations. Transcriptome and immune repertoire profiling from the preserved PBMC in the same blood sample provided complementary biomarker information to enable a comprehensive evaluation of the disease status of these samples.
Citation Format:
Anagha Kadam, Margaret R. Heider, Chen Song, Jian Sun, Ariel Erijman, Nicholas M. George. An optimized sample-to-result workflow for detection of tumor mutations and immune sequencing in liquid biopsies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 5879.
American Association for Cancer Research (AACR)
Title: Abstract 5879: An optimized sample-to-result workflow for detection of tumor mutations and immune sequencing in liquid biopsies
Description:
Abstract
Non-invasive liquid biopsies are helping advance various aspects of disease assessment including early detection, disease monitoring, and therapy selection, while also allowing for improved patient follow-up and economic efficiency over traditional tissue biopsies.
Plasma cell-free DNA (cfDNA) applications have recently been adopted in prenatal screening, tumor mutation profiling and post-transplant monitoring.
Additionally, combining cfDNA profiling with paired RNA analysis of peripheral blood mononuclear cells (PBMCs) can provide useful insights into biomarkers and immune phenotypes, and present a comprehensive multiomic profile from a single blood draw.
Several technical and analytical challenges persist in the liquid biopsy field including immediate preservation of draw time levels of cfDNA, minimizing PBMC lysis during storage, low concentrations of cfDNA with even lower tumor fraction, as well as the need for a higher sensitivity in downstream applications to accurately interpret clinical signals.
Here, we present an efficient blood-to-result workflow for tumor-specific mutation detection and immune profiling using contrived samples spiked with known mutation controls.
Whole blood was collected in Streck Nucleic Acid BCT enabling preservation of draw time concentration of cell-free nucleic acids and prevention of immune cell lysis.
Nucleic acid extraction was performed on the isolated PBMCs and plasma fraction using an optimized protocol for the Monarch Mag Viral DNA/RNA Extraction Kit which features a simplified, magnetic bead-based workflow.
Isolated cfDNA was used to prepare sequencing libraries using an optimized library prep workflow to maximize conversion efficiency from cfDNA.
Isolated PBMC RNA was utilized to prepare RNA-seq libraries and Immune-seq libraries using the NEBNext UltraExpress RNA Library Prep Kit and NEBNext Immune Sequencing Kit, respectively.
Combining these sample storage, extraction, and library prep methods resulted in a high yield of cfDNA libraries with minimal contaminating genomic DNA, enabling improved sequencing data quality, high conversion efficiency, and high sensitivity for clinical research, including detecting spike-in mutations.
Transcriptome and immune repertoire profiling from the preserved PBMC in the same blood sample provided complementary biomarker information to enable a comprehensive evaluation of the disease status of these samples.
Citation Format:
Anagha Kadam, Margaret R.
Heider, Chen Song, Jian Sun, Ariel Erijman, Nicholas M.
George.
An optimized sample-to-result workflow for detection of tumor mutations and immune sequencing in liquid biopsies [abstract].
In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL.
Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 5879.
Related Results
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract
A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Small Subclones Harboring NOTCH1, SF3B1 or BIRC3 Mutations Are Clinically Irrelevant in Chronic Lymphocytic Leukemia
Small Subclones Harboring NOTCH1, SF3B1 or BIRC3 Mutations Are Clinically Irrelevant in Chronic Lymphocytic Leukemia
Abstract
Introduction. Ultra-deep next generation sequencing (NGS) allows sensitive detection of mutations and estimation of their clonal abundance in tumor cell pop...
EPD Electronic Pathogen Detection v1
EPD Electronic Pathogen Detection v1
Electronic pathogen detection (EPD) is a non - invasive, rapid, affordable, point- of- care test, for Covid 19 resulting from infection with SARS-CoV-2 virus. EPD scanning techno...
Dynamics of Mutations in Patients with ET Treated with Imetelstat
Dynamics of Mutations in Patients with ET Treated with Imetelstat
Abstract
Background: Imetelstat, a first in class specific telomerase inhibitor, induced hematologic responses in all patients (pts) with essential thrombocythemia (...
MARS-seq2.0: an experimental and analytical pipeline for indexed sorting combined with single-cell RNA sequencing v1
MARS-seq2.0: an experimental and analytical pipeline for indexed sorting combined with single-cell RNA sequencing v1
Human tissues comprise trillions of cells that populate a complex space of molecular phenotypes and functions and that vary in abundance by 4–9 orders of magnitude. Relying solely ...
Detection of Compound BCR-ABL Mutations in TKI Resistant CML Patients Including a Novel K245N Mutation Associated with Primary Nilotinib Resistance By Employing a Newly Developed Cost Effective BCR-ABL Sequencing Protocol
Detection of Compound BCR-ABL Mutations in TKI Resistant CML Patients Including a Novel K245N Mutation Associated with Primary Nilotinib Resistance By Employing a Newly Developed Cost Effective BCR-ABL Sequencing Protocol
Abstract
Introduction: BCR-ABL mutations are the major background players in manifestation of resistance to all FDA approved tyrosine kinase inhibitors (TKIs) includ...
Distinct Profile of FLT3 Mutations in Brazil.
Distinct Profile of FLT3 Mutations in Brazil.
Abstract
Mutations in the tyrosine kinase receptor FLT3 are the most common molecular abnormality in acute myeloid leukemia (AML) being detected in about 30% of AML ...
Conjugate vaccines targeting the tumor vasculature
Conjugate vaccines targeting the tumor vasculature
Cancer cells acquire critical hallmarks which eventually facilitate the formation of malignant tumors. In this thesis, we highlighted two important hallmarks, the induction of angi...

